liso-cel

Amidst Legal Battle, BMS' CAR-T Therapy Scores Second FDA Approval
Amidst Legal Battle, BMS' CAR-T Therapy Scores Second FDA Approval
BioSpace
Bristol Myers Squibb
CAR-T
Breyanzi
liso-cel
FDA
large B-cell lymphoma
Flag link:
'Major blunder:' Ex-staffers blast Bristol Myers Squibb's handling of Breyanzi approval in latest CVR lawsuit update
'Major blunder:' Ex-staffers blast Bristol Myers Squibb's handling of Breyanzi approval in latest CVR lawsuit update
Fierce Pharma
Bristol Myers Squibb
legal
Breyanzi
shareholders
CAR-T
liso-cel
lymphoma
Flag link:
Bristol Myers scales up cell therapy production with liso-cel nod in hand and another approval maybe on the way
Bristol Myers scales up cell therapy production with liso-cel nod in hand and another approval maybe on the way
Endpoints
Bristol-Myers Squibb
drug manufacturing
cell therapy
liso-cel
CAR-T
Flag link:
Bristol Myers Squibb's CAR-T liso-cel wins long-delayed FDA nod
Bristol Myers Squibb's CAR-T liso-cel wins long-delayed FDA nod
Fierce Pharma
FDA
Bristol-Myers Squibb
liso-cel
CAR-T
Flag link:
FDA blasts Lonza facility in Form 483 that derailed Bristol Myers' plan of liso-cel nod by 2020
FDA blasts Lonza facility in Form 483 that derailed Bristol Myers' plan of liso-cel nod by 2020
Fierce Pharma
Bristol-Myers Squibb
Celgene
liso-cel
M&A
CAR-T
Flag link:
Aducanumab tops 2021’s biggest potential launches
Aducanumab tops 2021’s biggest potential launches
EP Vantage
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
Flag link:
An FDA inspection raises questions about Bristol Myers Squibb's liso-cel facility and the CVR, but analysts urge caution
An FDA inspection raises questions about Bristol Myers Squibb's liso-cel facility and the CVR, but analysts urge caution
Endpoints
Bristol-Myers Squibb
liso-cel
drug manufacturing
Celgene
CVRs
Flag link:
Could an FDA inspection scupper CVR deadline for BMS’ liso-cel?
Could an FDA inspection scupper CVR deadline for BMS’ liso-cel?
Pharmaforum
Bristol-Myers Squibb
liso-cel
CVRs
Flag link:
JW Therapeutics hauls in $300M IPO just as liso-cel-inspired CAR-T nears the finish line in China
JW Therapeutics hauls in $300M IPO just as liso-cel-inspired CAR-T nears the finish line in China
Endpoints
JW Therapeutics
IPOs
CAR-T
liso-cel
China
Hong Kong
Juno Therapeutics
WuXi AppTec
Flag link:
5 FDA approval decisions to watch in the 4th quarter
5 FDA approval decisions to watch in the 4th quarter
BioPharma Dive
FDA
drug approvals
vaccines
Pfizer
Moderna Therapeutics
COVID-19
Regeneron
EB3
ebola virus
Alkermes
ALKS-3831
schizophrenia
bipolar disorder
Bristol-Myers Squibb
liso-cel
non-Hodgkin lymphoma
roxadustat
FibroGen
chronic kidney disease
Flag link:
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
Endpoints
Bristol-Meyers Squibb
CAR-T
Celgene
ide-cel
Bluebird Bio
liso-cel
ozanimod
Flag link:
Blockbusters in waiting: drug launches to watch in 2020
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Flag link:
Bristol-Myers confident of approvals linked to higher Celgene investor payout: Bristol executive
Bristol-Myers confident of approvals linked to higher Celgene investor payout: Bristol executive
Reuters
Bristol-Myers Squibb
Celgene
M&A
liso-cel
ozanimod
bb2121
FDA
Flag link:
BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS
BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS
Fierce Pharma
Bristol-Myers Squibb
Celgene
M&A
ozanimod
liso-cel
bb2121
Flag link:
Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout
Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout
Biopharma Dive
ASH
Celgene
M&A
Bristol-Myers Squibb
liso-cel
Flag link:
Celgene posts pivotal CAR-T data ahead of FDA filing
Celgene posts pivotal CAR-T data ahead of FDA filing
Fierce Biotech
Celgene
CAR-T
liso-cel
Kymriah
Yescarta
Flag link:
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
Motley Fool
Vertex Pharmaceuticals
VX-445
tezacaftor/ivacaftor
AbbVie
upadacatinib
Daiichi Sankyo
trastuzumab deruxtecan
Celgene
liso-cel
Novartis
LY3298176
Flag link:
Celgene to launch five new products through to 2020
Celgene to launch five new products through to 2020
PM Live
Celgene
Revlimid
FDA
fedratinib
ozanimod
luspatercept
bb2121
liso-cel
Flag link:
ASCO18: Celgene makes its case as CAR-T rival in lymphoma
ASCO18: Celgene makes its case as CAR-T rival in lymphoma
Biopharma Dive
Celgene
JCAR017
liso-cel
CAR-T
B-cell non-Hodgkin lymphoma
ASCO 2018
Flag link: